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ABSTRACT
Introduction Exercise and physical activity (PA) are 
fundamental to the treatment of type 2 diabetes. Current 
exercise and PA strategies for newly diagnosed individuals 
with type 2 diabetes are either clinically effective but 
unsuitable in routine practice (supervised exercise) or 
suitable in routine practice but clinically ineffective (PA 
advice). Mobile health (mHealth) technologies, offering 
biometric data to patients and healthcare professionals, 
may bridge the gap between supervised exercise and PA 
advice, enabling patients to engage in regular long- term 
physically active lifestyles. This feasibility randomised 
controlled trial (RCT) will evaluate the use of mHealth 
technology when incorporated into a structured home- 
based exercise and PA intervention, in those recently 
diagnosed with type 2 diabetes.
Methods and analysis This feasibility multicentre, 
parallel group RCT will recruit 120 individuals with type 
2 diabetes (diagnosis within 5–24 months, aged 40–75 
years) in the UK (n=60) and Canada (n=60). Participants 
will undertake a 6- month structured exercise and PA 
intervention and be supported by an exercise specialist 
(active control). The intervention group will receive 
additional support from a smartwatch and phone app, 
providing real- time feedback and enabling improved 
communication between the exercise specialist and 
participant. Primary outcomes are recruitment rate, 
adherence to exercise and loss to follow- up. Secondary 
outcomes include a qualitative process evaluation and 
piloting of potential clinical outcome measures for a future 
RCT.
Ethics and dissemination The trial was approved in the 
UK by the South East Scotland Research Ethics Committee 
01 (20/SS/0101) and in Canada by the Clinical Research 
Ethics Board of the University of British Columbia (H20- 
01936), and is being conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice. Results 
will be published in peer- reviewed journals and presented 
at national and international scientific meetings.
Trial registration numbers ISRCTN14335124;  
ClinicalTrials. gov: NCT04653532.
INTRODUCTION
Increasing physical activity (PA: move-
ment that raises energy expenditure), both 
through exercise (planned and structured 
PAs with a goal of improving health and 
fitness) and habitual lifestyle behaviours such 
as walking and active travel, is fundamental to 
the initial treatment of type 2 diabetes,1 and 
is recommended by international consensus.2 
Nevertheless, individuals with type 2 diabetes 
are less active and more sedentary than those 
without.3 4 To address this issue, diabetes 
care pathways are prioritising personalised 
exercise and PA advice for those with newly 
diagnosed type 2 diabetes, (eg, the National 
Strengths and limitations of this study
 ► The MOTIVATE intervention potentially allows pa-
tients with newly diagnosed type 2 diabetes to 
co- design a personalised and progressive exer-
cise programme with the support of an exercise 
specialist.
 ► The MOTIVATE intervention potentially allows par-
ticipants to communicate regularly with an exercise 
specialist and gain feedback on the exercise they 
complete.
 ► Our active control group matches the contact time 
provided to the mobile health (mHealth) group in 
order to assess how the addition of mHealth tech-
nologies can increase exercise and physical activity 
(PA) adherence.
 ► The 12- month follow- up enables monitoring and 
evaluation of long- term adherence to an mHealth 
exercise and PA intervention.
 ► The MOTIVATE intervention is not embedded within 
current healthcare systems, as such, future work 
will be needed to address how the intervention could 
fit within current clinical care.  on D
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Health Service (NHS) Rightcare Pathway in UK5 and 
Diabetes 360°6 in Canada).
Previous research studies show supervised exercise 
interventions in individuals with type 2 diabetes are 
useful as they can increase total PA7 and reduce glycated 
haemoglobin (HbA1c) by −0.67% (1.3 mmol/mol),8 a 
reduction comparable with that observed with the addi-
tion of non- insulin glucose- lowering drugs.9 However, the 
resources required to implement supervised exercise are 
not feasible as part of routine care in many countries.10 
Standard provision for individuals with newly diagnosed 
type 2 diabetes therefore is limited to PA advice alone. 
Importantly, a meta- analysis8 suggests PA advice was not 
associated with changes in HbA1c in individuals with type 
2 diabetes, unless it was combined with dietary advice.7 
Therefore, in order to provide effective exercise and PA 
support to individuals with type 2 diabetes, research is 
needed to develop clinically effective, cost- effective, scal-
able interventions which bridge the gap between super-
vised exercise and PA advice.
The emergence of mobile technologies and wearable 
sensors has enabled real- world monitoring of mobile 
health biometrics (mHealth). Devices incorporating 
biometrics such as habitual PA and heart rate (HR) 
could be a potential solution to bridge the gap between 
supervised exercise and PA advice (figure 1). The use 
of PA monitors (pedometers or accelerometers) is asso-
ciated with increases in daily PA in individuals with type 
2 diabetes,11 12 which can be maintained for up to 12 
months.11 While some data suggest a sustained increase 
in PA may be beneficial for improving cardiovascular and 
general health,13 PA monitoring in combination with 
advice has not yielded clinically meaningful improve-
ments in HbA1c.8 It is hypothesised that the lack of mean-
ingful improvement in HbA1c may be due to the fact that 
PA monitors promote low intensity habitual PA rather 
than more intense domains,11 12 which are essential for 
improving glycaemic control.14 As such, PA monitoring 
is a good strategy to support habitual PA goals, but to 
improve HbA1c this technology may need to be combined 
with strategies that promote activities of greater exercise 
intensity.
HR monitors provide objective personalised data that 
account for age, body mass and fitness15 and are related 
to exercise intensity regardless of the type of activity being 
performed.16 Recently, HR monitors have been used to 
promote adherence to structured home- based exercise 
programmes in people with type 1 diabetes and individ-
uals with obesity and an elevated cardiovascular disease 
(CVD) risk.17 18 Importantly, in both studies, >90% adher-
ence to the prescribed exercise sessions was observed, 
with >85% of sessions completed at the prescribed inten-
sity, resulting in improved aerobic capacity17 18 and insulin 
sensitivity.18 Qualitative data from an online survey in 
people with type 1 diabetes suggested that the availability 
of real- time feedback during exercise contributed to 
the high adherence.17 It is hypothesised that safe prac-
tice of exercise at intensities known to influence clinical 
outcomes through the provision of real- time feedback 
fosters self- efficacy to engage in exercise, an important 
predictor of future exercise engagement.19 Therefore, 
the combination of accelerometry and optical HR moni-
toring available in commercial wrist- worn smartwatches 
may be the most effective tool to facilitate a personalised 
home- based intervention, promoting both habitual PA 
and appropriate intensity- structured exercise that influ-
ences clinical outcomes (eg, HbA1c).
Another potentially useful aspect of mHealth tech-
nologies is that they can facilitate support from health-
care providers (HCPs), which is another significant 
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barrier to unsupervised exercise and PA interventions.20 
Online cloud- based portals allowing biometric data 
sharing between individuals and HCPs, and remote 
communication platforms, have been developed. Such 
technology could be used to facilitate communica-
tion (or ‘coaching’), aiming to mimic the relationship 
experienced during supervised interventions. Taken 
together, there is accumulating evidence that mHealth 
technologies may increase adherence to unsupervised 
exercise/habitual PA programmes and improve clinical 
outcomes.
Study aims
The primary aim of the study is to undertake a feasibility 
randomised controlled trial (RCT) in adults with newly 
diagnosed type 2 diabetes evaluating a theoretical model 
where mHealth technology, allowing biometric informed 
feedback and coaching, is incorporated into a structured 
home- based exercise and PA intervention. Our overall 
objective is to inform an evidence- based exercise and PA 
intervention ready to evaluate in a future RCT.
The specific objectives are:
1. Determine the number of adults with newly diagnosed 
type 2 diabetes who are eligible to participate within 
the UK and Canada, and the proportion of these who 
would be willing to take part in this trial (ie, recruit-
ment rate).
2. Define the rates of adherence to the interventions and 
the number of participants retained at 12 months in 
both arms of the trial (ie, participant drop- out).
3. Estimate precision of potential outcome measures re-
quired for sample size estimations for the definitive 
RCT. The main outcome measures are glycaemic con-
trol (HbA1c and flash glucose monitoring), lipid pro-
file, blood pressure, body composition, PA and quality 
of life.
4. Evaluate the acceptability of the intervention.
5. Pilot methods for collecting outcome measures, re-
cruitment, randomisation, treatment and follow- up.




A feasibility multicentre, parallel group, RCT, whereby 
participants will complete pre- randomisation baseline 
assessments before allocation to exercise counselling 
(active control) or exercise counselling plus mHealth 
(intervention). Participants will repeat PA and flash 
glucose monitoring in the final 14 days of the interven-
tion and all other health measurements immediately 
post- intervention (6 months). All measurements will 
be carried out again 6 months after the intervention is 
completed (follow- up) (figure 2). The trial protocol 
adheres to Recommendations for Interventional Trials21 
and the Template for Intervention Description and Repli-
cation22 guidelines.
Study setting and recruitment plan
Recruitment of 120 participants to the trial will take place 
over 12 months commencing January 2021 and will be 
completed in December 2021 in the UK (n=60) and from 
February 2021 to January 2022 in Canada (n=60). The 
trial will end (last data collection from the last partic-
ipant) in January 2023. In the UK, participants will be 
recruited from (1) general practitioner (GP) database 
searches across 22 practices in: the North West (n=18), 
West Midlands (n=1), South West (n=2) and London 
(n=1); (2) identification of patients by clinical staff 
at participating GP practices in: Bristol, Birmingham, 
Cambridge, Devon, Dorset, Leeds, Manchester, Norfolk, 
Oxford, Somerset, Southampton, York and three London 
Boroughs. Staff will approach patients and direct patients 
to the trial website ( www. MotivateT2D. com); (3) flyers 
provided to diabetes education sessions run through 
community clinics across the Liverpool and Knowsley 
areas; and (4) posters displayed in high traffic areas 
within the healthcare system, social media and diabetes 
websites. In Canada, participants will be recruited from 
(1) waiting room advertisements posted in: GP clinics 
across British Columbia and Alberta (n=10), laboratories 
across British Columbia (n=5) and pharmacies across the 
interior region of British Columbia (n=28); (2) adver-
tisements on the Diabetes Canada social media sites; (3) 
third party clinical trial recruitment services (n=2); (4) 
local online classified ads and print media sites; and (5) 
partnerships with national, provincial and university- wide 
PA initiatives. The impact of the different recruitment 
strategies used in the UK and Canada will be explored to 
inform the design of the future RCT.
Eligibility criteria
Population
Eligible participants will have a recent clinical diagnosis 
of type 2 diabetes (within the previous 5–24 months) 
and will be aged between 40 and 75 years. Participants 
managed by lifestyle modifications alone or metformin 
(stable dose for ≥3 months) will be eligible.
Potentially eligible participants will be consented and 
screened via video call (Zoom Video Communications, 
2016). This involves a medical history, details of current 
medications, current PA and exercise behaviour. Eligi-
bility for blood pressure and HbA1c will be confirmed 
during baseline assessment. Should a participant’s blood 
pressure or HbA1c be outside the inclusion criteria, they 
will be excluded at this point.
Detailed inclusion criteria
1. Clinical diagnosis of type 2 diabetes within the previ-
ous 5–24 months.
2. Aged 40–75 years.
3. Diabetes treated with diet or metformin (stable dose 
for 3 months or more).
Detailed exclusion criteria
1. Aged <40 or >75 years.
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2. HbA1c >86 mmol/mol (>10%).
3. Blood pressure >160/100 mm Hg.
4. Glucose- lowering agents other than metformin.
5. Insulin or GLP- 1.
6. Unstable angina.
7. Myocardial infarction within the previous 3 months.
8. Transient ischaemic attack in the previous 6 months.
9. Heart failure New York Health Association 
(NYHA) ≥class II.
10. Arrhythmia.
11. Healthcare professional has advised against increas-
ing level of activity.
12. Pregnancy or planning to become pregnant.
13. <6 months post partum or stopped breast feed-
ing <1 month before recruitment.
14. Not owning a smartphone/or having no data plan or 
access to WiFi.
15. Currently meeting the recommended exercise guide-
lines (150 min of moderate intensity exercise per 
week).
Randomisation and blinding
Participants will be randomised to intervention (mHealth) 
or active control on a 1:1 basis using a computer- generated 
Figure 2 Trial design and participant pathway. GLTEQ, Godin Leisure Time Exercise Questionnaire; mHealth, mobile health.
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random allocation sequence, created and administered 
by the Centre for Health and Evaluation and Outcome 
Sciences. Randomisation will be stratified by centre (UK 
or Canada), sex (male or female) and age (40–60 or 61–75 
years). To ensure allocation concealment, researchers 
will request randomisation on completion of all baseline 
assessments. Permuted blocks of random size 4 and 6 for 
each stratum will be used. Due to the nature of the inter-
vention, blinding of the participants or researchers deliv-
ering the interventions is not possible.
Outcome measures
In light of disruptions caused by the COVID- 19 pandemic, 
outcome measures will be taken using remote ‘home- 
based’ solutions which do not require travel or in- person 
contact. To enable this approach, participants will be 
mailed all the necessary assessment resources. Videos 
and written guidelines explaining the assessments will 
be available electronically ( www. motivatet2d. com), and 
participants will receive support from a member of the 
research team prior to and on the day of assessments.
Primary outcome
The primary outcomes are recruitment rate and partici-
pant drop- out. Information will be collected on (1) the 
number of patients approached and the reasons for not 
participating; and (2) the percentage of participants 
completing the follow- up assessment time point and 
reasons for drop- out, so that a full Consolidated Stan-
dards of Reporting Trials diagram can be generated. 
Information will be gathered on participants’ age, sex, 
duration since diabetes diagnosis, ethnicity, postcode/zip 
code, marital status, living arrangements, education and 
employment status.
Secondary outcomes
A number of outcome measures will be piloted to obtain 
estimates of key trial parameters to inform future sample 
Table 1 Tests/questionnaires conducted at baseline, 6 and 12 months
Measured Measurement strategy Outcome
Exercise adherence and 
habitual PA
Device- derived exercise assessment 1. Number of structured exercise sessions
2. Exercise duration
3. Exercise intensity
14- day device- derived PA 1. Device wear time
2. Average minutes of total, light, moderate, vigorous and moderate- to- 
vigorous PA per day
3. Average minutes of sedentary time per day
4. Moderate- to- vigorous PA in bouts ≥10 min
5. PA volume
6. Average intensity
Survey- reported exercise behaviour 
(GLTEQ)
1. Bouts of mild, moderate and strenuous exercise lasting ≥30 min
2. Weekly leisure- time exercise
Anthropometrics Home- based measures Height, weight, waist circumference
Blood pressure Home- based measures Systolic and diastolic blood pressure
Biochemistry Fasting home- based blood collection 1. Cholesterol, HDL- C, LDL- C, non- HDL- C, triglycerides
2. HbA1c
Glycaemic control 14- day flash glucose monitoring 1. Device wear time
2. Mean glucose
3. Estimated A1c
4. Glycaemic variability (%CV and SD)
5. Time above range (L1 >10 mmol/L, L2 >13.9 mmol/L)
6. Time in range (3.9–10.0 mmol/L)
7. Time below range (L1<3.9 mmol/L, L2<3.0 mmol/L)
8. LBGI and HBGI (risk indices)
9. Episodes (hypoglycaemia and hyperglycaemia) 15 min
10. Area under the curve
Questionnaires Qualtrics online survey 1. BREQ- 2
2. SF- 12 Health Survey
3. DTSQs
4. DTSQc
5. 5- level EQ- 5D
6. Patient Rapport with Counsellor Questionnaire
BREQ- 2, Behavioural Regulation in Exercise Questionnaire version 2; %CV, percentage coefficient of variation; DTSQc, Diabetes Treatment 
Satisfaction Questionnaire change version; DTSQs, Diabetes Treatment Satisfaction Questionnaire status version; EQ- 5D, EuroQol- 5 Dimensions 
questionnaire; GLTEQ, Godin Leisure Time Exercise Questionnaire; HbA1c, glycated haemoglobin; HBGI, high blood glucose index; HDL- C, high- 
density lipoprotein cholesterol; LBGI, low blood glucose index; LDL- C, low- density lipoprotein cholesterol; L1>10 mmol/L, level 1 hyperglycaemia; 
L2>13.9 mmol/L, level 2 hyperglycaemia; L1<3.9 mmol/L, level 1 hypoglycaemia; L2<3.0 mmol/L, level 2 hypoglycaemia; PA, physical activity; SF- 12, 
12- Item Short Form Survey.
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size estimations (table 1). Unless stated below, outcomes 
will be assessed in all participants at baseline, post- 
intervention and follow- up.
Exercise adherence and habitual PA
Adherence to a long- term home- based exercise prescrip-
tion is difficult to measure using one method. Three 
assessment measures will be piloted:
1. Device- derived assessment of exercise sessions: the number of 
planned structured exercise sessions completed along 
with the duration and intensity of each session will be 
assessed via optical HR monitoring (photoplethysmog-
raphy). The mHealth group will use the Ignite fitness 
watch (Polar Electro, Finland) provided as part of the 
intervention. The active control group will be provid-
ed with a Polar Verity Sense (Polar Electro, Finland) 
optical HR monitor for the duration of the trial, to 
wear during planned structured exercise sessions. The 
Polar Verity Sense records HR but gives no real- time/
historical feedback to participants, as such active con-
trol participants will be blinded to the HR throughout.
2. Device- derived PA: key metrics of PA (table 1) will be as-
sessed using a wrist- worn triaxial accelerometer (GE-
NEActiv, Activinsights, Kimbolton, Cambridge, UK) 
for 14 days (a) immediately following baseline assess-
ments/prior to commencement of the intervention; 
(b) during the final 14 days of the intervention period 
and (c) immediately after follow- up testing. The accel-
erometer will be initialised and set to start and finish 
recording at specific dates by the research team before 
sending to the participant. Data will be downloaded 
using manufacturers’ software and processed in R (R 
Core Team,Vienna, Austria) using the open- source 
GGIR software package (http:// cran. r- project. org).
3. Survey- reported exercise behaviour will be evaluated us-
ing the Godin Leisure Time Exercise Questionnaire23 
at baseline, post- intervention, follow- up and every 
4 weeks during the 12- month trial period. The ques-
tionnaire will be administered using online survey soft-
ware (Qualtrics; www. qualtrics. com).
Anthropometrics and blood pressure
The degree of obesity in an individual with type 2 diabetes 
is an important modifiable risk factor for long- term 
health.24 In addition, elevated blood pressure is linked to 
increased risk of CVD in type 2 diabetes.25 As such, body 
mass, height, waist circumference and blood pressure will 
be measured by participants. Participants will be sent a 
tape measure (Seca 201, Germany), electronic scales 
(Salter, UK) and automated blood pressure monitor 
validated by the British and Irish Hypertension Society 
(UK, Salter BPA- 9200- GB; Canada, Bios BD215). Partici-
pants will be asked to record their height if known; if not, 
participants will use the tape measure to record height. 
Waist circumference will be measured at the level of the 
umbilicus. Self- measured blood pressure is a validated 
approach for monitoring blood pressure, endorsed by 
the American Heart Association and American Medical 
Association.26 Previous work suggests a strong correlation 
between self- measured and technician- measured height 
and weight27 and waist circumference, measured at the 
umbilicus.28
Blood sampling
Elevated levels of HbA1c and blood lipids are linked to 
increased risk of cardiovascular complications in type 2 
diabetes.25 As such, fasting blood samples will be taken 
to assess HbA1c and lipid profile. Participants in both 
the UK and Canada will collect a 500 µL capillary blood 
sample from a finger prick, using a commercial blood 
collection kit. Blood collection kit preparation and 
sample analysis will be performed by the Exeter Clinical 
Laboratory, based at the Royal Devon and Exeter NHS 
Foundation Trust. In the UK, samples will be sent directly 
to the Exeter Clinical Laboratory for analysis, via Royal 
Mail. In Canada, participants will send samples to the 
research team at the University of British Columbia, via 
Canada Post. Once samples are received, they will be 
centrifuged and stored at –80°C before being shipped 
on dry ice to the Exeter Clinical Laboratory for analysis. 
Internal pilot data from the Exeter Clinical Laboratory 
demonstrate that capillary blood sampling reveals good 
agreement with standard venous sampling. In Canada, to 
ensure participants meet the inclusion criteria (HbA1c 
≤86 mmol/mol), 5 µL of the sample will be used by the 
research team at the University of British Columbia to 
measure HbA1c, unless this can be confirmed by a recent 
(within 1 month) test conducted by a standard clinical 
lab. If required, the Afinion 2 point- of- care (POC) anal-
yser (Alere Technologies, Osla, Norway) will be used for 
this screening. The Afinion 2 is a National Glycohemo-
globin Standardization Program- certified POC device for 
evaluating HbA1c29 and has shown low rates of bias and 
imprecision from standardised testing by the College of 
American Pathologists.30
Flash glucose monitoring
Although HbA1c is recognised as the key marker for 
the development of diabetes complications, it does not 
provide information on the magnitude and frequency of 
intraday and interday glucose variation, which are also 
important predictors of future diabetes complications.31 
As such, key metrics of glycaemic control31 (table 1) 
will be assessed using a flash glucose monitor (FreeStyle 
Libre Pro, Abbott Diabetes Care, Alameda, California, 
USA) worn for 14 days (1) immediately following base-
line assessments/prior to commencement of the inter-
vention; (2) during the final 14 days of the intervention 
period and (3) immediately after follow- up testing.
Questionnaires
Generic health status (5- level EuroQol- 5 Dimensions 
questionnaire32) health- related quality of life (12- Item 
Short Form Survey (SF- 12) Health Survey33), diabetes 
treatment satisfaction (Diabetes Treatment Satisfaction 
Questionnaire status version (DTSQs)34) and motivation 
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to exercise (Behavioural Regulation in Exercise Question-
naire version 235) will be assessed using online versions 
of the surveys administered using Qualtrics. At post- 
intervention, only change in diabetes treatment satisfac-
tion (DTSQ change version36) and participant rapport 
with their counsellor (10- point scale of Client Experi-
ences of Motivational Interviewing37) will be assessed.
Process evaluation
A detailed process evaluation will examine the accept-
ability and feasibility of the intervention and evaluation 
methods. Semistructured interviews will be conducted at 
four time points (table 2):
1. Acceptability of virtual assessment procedures—follow-
ing pre- randomisation baseline assessment.
2. Post- intervention feedback on the intervention—6 
months post- randomisation.
3. Post- intervention feedback on acceptability of the re-
search process—6 months post- randomisation.
4. Follow- up feedback on continuity of exercise and 
PA after intervention concluded—12 months 
post- randomisation.
All interviews will be via telephone or video call 
according to participant preference and will be struc-
tured using a topic guide.
Qualitative analysis
Interviews will be deductively coded and analysed using 
the theoretical domains framework,38 which is an effi-
cient means to characterise challenges and facilitators 
experienced in interventions as they are being refined, as 
well as highlight potential mediators influencing efficacy 
of intervention components.39 This methodology has 
been used extensively in the health behavioural change 
sciences.40 41 Interview audio files will be transcribed 
verbatim. Transcriptions will be subject to deductive 
thematic analysis using NVivo V.12TM software.
Analyses will be conducted in the following steps: 
(1) exporting the textual data from the transcriptions 
into NVivo; (2) reading and rereading the data inde-
pendently by two experienced coders; (3) documenta-
tion of ‘researcher memos’ following the initial reading 
of the data; (4) associating preliminary themes associated 
with the theoretical domains framework through line- 
by- line coding of transcriptions; (5) grouping codes that 
represent familiar phenomena/themes; and (6) further 
defining/refining themes through subsequent review of 
data to gain coder consensus. Member checking42 will be 
the final step in analysis, ensuring that interviewed partic-
ipants have the opportunity to confirm researcher inter-
pretation and add comments that will be incorporated 
into the final analysis. Consolidated criteria for Reporting 
Qualitative research guidelines43 will be adhered to in 
reporting of these qualitative data. Our aim is to develop 
a comprehensive understanding of the intervention 
acceptability, implementation and mechanisms of impact.
Economic assessment
At baseline, post- intervention and follow- up, all partici-
pants will complete the EuroQol- 5 Dimensions- 5 Levels 
Table 2 Details of semistructured interviews
Interview Group sampled
Number 
sampled in each 
country





 ► Active control
4 (8)  ► The first 4 
participants to 
consent
 ► Stratified for age 
(40–60 and 61–75)
Approximately 
1 week after pre- 
randomisation 
baseline testing
Learn about experiences (ease and 
willingness, comprehension and ability 
to follow instructions, length of time to 
complete, suggestions for improvement) 
with home- based baseline testing
Post- intervention 
feedback on the 
intervention
Intervention only 6–10 (12–20)  ► Stratified for age 
(40–60, 61–75)
 ► Minimum of one 
self- identified male 
and female
Approximately 
1 week after the 
intervention period 
is completed
Learn about experiences (barriers, 
facilitators, actual use of technology and 
coach, receptivity to the coach, perceived 
appropriateness and suggestions for 
improvement) with the intervention 







 ► Active control
6–10 (12–20)  ► Stratified for age 
(40–60, 61–75)
 ► Minimum of one 
self- identified male 
and female
Approximately 
1 week after post- 
intervention testing
Learn about experiences (willingness 
to do the study again, refer others, 
perceived appropriateness, respect, 
dignity, confidentiality and suggestions 
for improvement) with recruitment, 
randomisation and the research process
Follow- up 
feedback on 




 ► Active control
 ► Intervention: 
6–10 (12–20)
 ► Control: 6–10 
(12–20)
 ► Stratified for age 
(40–60, 61–75)
 ► Minimum of one 
self- identified male 
and female
Approximately 
1 week after 
the follow- up 
assessment
Learn whether, and how, participants 
adhered to the exercise prescription, 
what facilitated and hindered this 
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questionnaire and a study- specific questionnaire assessing 
healthcare usage in the last 12 weeks (GP services, specialist 
care, ambulatory clinics in hospital, physiotherapy and 
medicines). During the interventions, researcher time 
per participant will also be recorded in both groups.
Interventions
Participants will be randomised to one of two arms:
1. Active control: exercise counselling.
2. Intervention arm: exercise counselling plus mHealth.
By design, the active control arm matches the provision 
provided to the intervention group, minus the provision 
of technology, as our aim is to investigate how the addi-
tion of mHealth technology can increase exercise and PA 
adherence and clinical outcomes.
All participants will undertake a 6- month structured 
exercise and PA intervention supported by an exercise 
specialist. Participants will co- design a personalised and 
progressive exercise programme. Each individual partic-
ipant’s exercise programme will differ (initial duration 
and intensity of sessions and rate of progression) but 
the aim will be to increase exercise intensity and dura-
tion during the first 12 weeks to meet the PA guidelines 
of 150–300 min of moderate- to- vigorous intensity PA per 
week by the end of this time period.13 44 Participants will 
be given a choice of exercise types (traditional endurance, 
interval exercise, resistance training, exercise classes, 
dance or sports) and modes (gym, outdoor, home- based 
or commuting) depending on personal preferences and 
available options to increase adherence and feasibility in 
daily life. Participants will also be encouraged to increase 
their daily PA. From 12 weeks onwards, the participants 
will be encouraged to at least maintain the level of exer-
cise (duration, intensity and frequency of sessions).
Active control: exercise counselling
Exercise and PA counselling
To assist participants with the transition to independent 
exercise and to promote long- term exercise adherence, 
participants will receive a behavioural exercise counsel-
ling intervention built into the 6- month exercise training 
programme. Participants will have five virtual counselling 
sessions with their exercise specialist over the 6- month 
intervention. The content of these meetings is based on 
the type 2 diabetes specific consultation guide developed 
by the ‘Moving Medicine’ initiative (http:// movingmed-
icine. ac. uk/ disease/ diabetes/) and the Brief Action 
Planning guide and flow chart developed by the Centre 
for Collaboration Motivation and Innovation (https:// 
centrecmi. ca/ brief- actionplanning/# 1502747767988- 
85883f98- 7299). Details of each counselling session are 
outlined in table 3.
Exercise prescription delivery
After exercise counselling session 2, participants will be 
sent a copy of their personalised exercise programme 
(booklet) which includes calendar and progressive exer-
cise guides. Exercise videos will also be available on the 
trial website ( www. motivateT2D. com). The exercise 
programme will be updated after exercise counselling 
sessions 3 and 4.
Ongoing communication with exercise specialist
Text messages will be sent weekly during the first 3 
months and biweekly during months 4–6. The messages 
will be pre- scripted, based on self- determination theory 
and modelled45 to target relatedness, competence and 
autonomy. Participants will not be required to reply but 
will have the option to, should they want to comment or 
ask a question.
Intervention arm: exercise counselling plus mHealth
Exercise and PA counselling
The counselling used within the intervention will follow 
the same format as active control, with additions on how 
to use the mHealth technology and HR to guide exercise 
intensity. Consultations 3, 4 and 5 will also be modified 
to allow participant feedback on exercise sessions (see 
below) and data recorded in the smartphone app and 
online coaching platform to guide discussions.
Exercise prescription delivery
The intervention arm includes three mHealth elements: 
(1) an online coaching platform for the exercise specialist 
Table 3 Details of the counselling intervention
Date Details
Consultation 1 Prior to 
intervention
Initial meeting to assess current beliefs/concerns, explore the benefits of exercise and 
agree on a SMART (specific, measurable, achievable, relevant and time- bound) plan
Consultation 2 Prior to 
intervention
Development of the personal exercise programme and education on exercise intensity
Consultation 3 Month 1 Patient feedback and refinement of the exercise programme with the aim of progressing 
the programme
Consultation 4 Month 3 Patient feedback and refinement of the exercise programme with the aim of progressing 
the programme, or maintaining if the government guidelines are being met
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(Polar Flow for Coach, www. polar. com/ coach); (2) a 
smartphone app for the participant (Polar Flow—Sync & 
Analyze) and (3) a wrist- worn fitness watch (Polar Ignite, 
Polar Electro). These three elements will be synchronised 
allowing data transfer between platforms.
Online platform for coach: within this platform, the 
exercise specialist will build the co- designed exercise 
programme, specifying the agreed number of sessions 
per week and modality of exercise. The exercise specialist 
will input the individual exercise sessions, prescribing the 
duration and intensity (measured through HR) of each 
phase within the session, that is, warm up, workout and 
cool down. These detailed exercise sessions will then be 
available as preset sessions on the participant’s fitness 
watch. Throughout the intervention, the online platform 
will also provide the exercise specialist with access to the 
participants’ training and PA data including: daily PA, HR 
traces from exercise sessions, Rating of Perceived Exer-
tion (RPE, CR- 10 scale46) following exercise sessions and 
written comments on exercise sessions.
Smartphone app for participant: participants will use the 
app to access their training programme and to track exer-
cise and PA achievements. All data recorded by the fitness 
watch will be available within the app, and participants 
will be able to provide feedback on each exercise session 
including sessions, RPE (CR- 10 scale46) and a written 
comment on each exercise session.
Fitness watch: the Polar Ignite fitness watch features a 
triaxial accelerometer and optical HR monitor. Prog-
ress towards a personalised PA target will be displayed 
throughout the day on the watch screen. Participants 
will be able to access preset exercise sessions, designed 
by their exercise specialist, on the device. The prescribed 
duration and intensity, via HR zones, will be displayed in 
real time on the watch throughout the exercise session. 
The watch will also provide live visual and haptic (vibra-
tion) alerts, coaching participants to execute the session 
as prescribed. Should participants not wish to use preset 
exercise sessions, the monitor screen will still provide live 
visual feedback on exercise time and intensity (current 
HR). All data recorded on the watch will be synchronised 
with both the smartphone app and the online platform.
Exercise videos will also be available to participants 
on the trial website ( www. motivateT2D. com). Videos 
will be formatted to fit with the preset exercise sessions 
prescribed to participants.
Ongoing communication with exercise specialist
During the first month, participants will be asked to 
provide RPE and written comments following all exercise 
sessions, using the app. The comment will relate to the 
appropriateness of the session duration and intensity and 
their enjoyment of the session and exercise type. After 
each recorded exercise session, the exercise specialist will 
then use the feedback provided to send a personalised 
text message in response to the session. Based on this 
feedback, the exercise specialist will update the training 
programme and preset exercise sessions as appropriate, 
using the online platform. The aim of this initial period is 
to refine the exercise sessions to ensure participants have 
a programme that fits with their current fitness, lifestyle 
and exercise goals.
Following exercise counselling 3 (1 month), partici-
pants will receive weekly text messages from their exer-
cise specialist. The exercise specialist will continue to 
use the data recorded in the online platform to provide 
personalised messages on exercise sessions and daily PA 
goals. Participants will not be asked to leave feedback 
after each exercise session during this period, but if feed-
back is provided, it will be used to guide the messages. 
During months 4–6, the frequency of the text messages 
will reduce to biweekly.
Exercise specialists
The role of exercise specialist will be assumed by a post-
doctoral research fellow in the UK (PhD in exercise phys-
iology) and a PhD student in Canada (MSc in exercise 
physiology). The same exercise specialist will provide 
support to both arms of the trial. To promote the fidelity 
of intervention delivery and to ensure the behavioural 
change, techniques are administered as intended, a 
comprehensive counsellor training workshop will be 
delivered to the two exercise specialists by an expert in 
health behaviour change counselling from the Diabetes 
Prevention Research Group at the University of British 
Columbia.
Ongoing management of diabetes
Management of diabetes, lipids and blood pressure will 
not be provided by the study team. In the UK, if alter-
ations to medications are needed, GPs will be encour-
aged (via a GP letter) to do so according to the targets 
suggested by The National Institute for Health and Care 
Excellence (NICE) guidance on management of diabetes 
(NG28) and hypertension (NG136) and lipid modifica-
tion (CG181). In Canada, family physicians who care for 
patients with type 2 diabetes are informed by the Diabetes 
Canada Clinical Practice Guidelines.44 Participants will be 
asked to inform the exercise specialist of any changes to 
their medications throughout the trial.
Study withdrawal
If a participant wishes to withdraw from the trial, the 
importance of providing outcome measures will be 
explained. Data collected up to withdrawal will be 
included. If the participant explicitly states their wish not 
to contribute further data to the study, an End of Study 
Case Report Form will be completed documenting the 
reason for withdrawal.
Serious adverse event reporting and monitoring
All adverse events will be reported and assignment 
of the severity/grading (mild, moderate, severe, life- 
threatening, death) made by the investigator respon-
sible for the care of the participant. The assignment of 
causality will be made by an independent clinician in the 
UK and Canada. All non- serious adverse events (SAEs), 
 on D
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whether expected or not, will be recorded and updated 
at each visit. All new SAEs will be reported from the point 
of consent until follow- up. Investigators will report SAEs 
to the sponsor within 24 hours of the local site becoming 
aware of the event. All adverse events will be followed 
until satisfactory resolution.
Data management
Data will be collected and stored in accordance with the 
Data Protection Act 1998/General Data Protection Regu-
lation 2018 in the UK and in accordance with British 
Columbia’s Freedom of Information and Protection of 
Privacy Act 2015 in Canada.
All data will be entered electronically. Outcomes and 
questionnaire data collected by participants will be 
reported using online survey software (Qualtrics; www. 
qualtrics. com). Blood reports will be sent via email to 
the UK and Canadian sites. The administrative data-
base (ie, participant information) and trial data will be 
managed by the research teams at the UK and Canadian 
sites. Random checks will be performed on the entered 
data against online records. All errors will be logged and 
corrected. All data will be stored on password- protected 
and encrypted computers. Participant files will be main-
tained in storage for a period of 15 years after completion 
of the trial, with access granted to the local research team 
only.
Our intended policy is that the research team should 
have exclusive use of the data for a period of 12 months 
or until the data are published. Data will be shared with 
named collaborators during this time. Following this time 
period, data will be made publicly available through the 
Liverpool John Moores University (LJMU) Data Reposi-
tory, published under a permissive reuse license.
Statistical analysis plan
The proportion of eligible participants who consent 
will be presented by centre and overall, along with the 
proportions in each intervention group completing each 
follow- up assessment and the reasons for withdrawal. 
Exploratory analyses on the predefined secondary 
outcomes will include a constrained baseline longitu-
dinal analyses via linear mixed model with fixed effects 
of time point, stratified allocation factors, and the inter-
action between time point and group, and random 
effects for participants. Effect estimates with 95% CI for 
between- group differences, and changes within group 
over time, will be reported. Interview data will be anal-
ysed as outlined above, which will allow the research 
team to discuss emerging themes and refine the interven-
tion protocol and trial design (eg, inclusion and exclu-
sion criteria and approach to participants) to maximise 
recruitment. The data collected within the trial will aid 
the Trial Steering Committee (TSC) in evaluating the 
study progression criteria (table 4), to inform a decision 
on whether a full RCT is warranted and feasible.
Sample size calculation
We aim to provide precise estimates of outcome vari-
ability that will aid in the planning of a definitive RCT.47 48 
A sample size of 60 per arm provides acceptably precise 
estimates of the variability in changes in outcome vari-
ables. For example, for outcomes measured as a propor-
tion, for example, drop- out rate, the 95% CI (modified 
Wald method) for a drop- out rate of, for example, 20% 
would be 12%–32%.47 A sample size of 60 per arm would 
also provide acceptably precise estimates of the variability 
in change in our primary outcome(s) and is higher than 
Table 4 Summary of progression criteria
Progression criteria Measures used
Assessment of whether criteria have been 
met
Feasibility to recruit participants to 
participate in the trial, with appropriate 
retention rates to 12- month follow- up
 ► % of participants recruited, and 
retained at each follow- up
 ► Regression models will identify 
predictors of loss to follow- up
 ► If >20% of new patients recruited=proceed; 
if <5%=full- scale trial unlikely to be feasible. 
If 5%–20%, the Trial Steering Committee 
(TSC) will consider proceeding.
 ► If >80% retained at 12 months=proceed, if 
<60%=full- scale trial unlikely to be feasible. 
If 60%–80%, the TSC will consider the 
feasibility of proceeding.
The intervention is acceptable to 
participants
 ► % of participants reporting 
acceptability on patient 
questionnaire
 ► Qualitative interviews
The TSC will consider the quantitative and 
qualitative data to judge acceptability.
Recruitment, randomisation and 
outcome measures are acceptable to 
>50% of recruited participants
 ► % of participants reporting 
acceptability on the patient 
questionnaire
 ► Qualitative interviews
 ► >50% report ‘agree’ or ‘strongly agree’ 
on the acceptability of recruitment and 
randomisation processes.
 ► The TSC will apply discretion in judging this 
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the median value for feasibility studies (36 participants 
per arm) reported in an audit of pilot and feasibility trials 
registered in the UK clinical research network.49
Trial oversight
Management structure
The trial will be overseen by a TSC and operated on a 
day- to- day basis by a Trial Delivery Group (TDG). Local 
Delivery Groups in the UK and Canada (UK: KH, HJ, VSS 
and MC; Canada: JLo and AMM) will produce monthly 
recruitment reports, to allow the TSC and TDG to regu-
larly review the trial across sites. The TSC will comprise 
of experienced medical experts and trialists. The TSC 
will also encompass the role of the Data Monitoring 
Committee. Meetings will be held at regular intervals 
dependent on need, but no less than once a year. The 
responsibilities of the TDG will include:
1. Report to the TSC.
2. Maintain the Trial Master File.
3. Confirm all approvals are in place before the start of 
the trial at a site.
4. Provide study materials.
5. Data management centre.
6. Give collaborators regular information about the 
progress of the study.
7. Respond to any questions (eg, from collaborators) 
about the trial.
8. Ensure data security and quality and observe data 
protection laws.
9. Safety reporting.
10. Ensure trial is conducted in accordance with Good 
Clinical Practice (GCP).
11. Statistical analysis.
12. Publication of trial results.
The role of the TSC is to provide overall supervision of 
the trial. In particular, the TSC will concentrate on the 
progress of the trial, adherence to the protocol, partici-
pant safety and consideration of new information. The 
TSC must be in agreement with the final protocol and, 
throughout the trial, will take responsibility for:
1. Major decisions such as need to change the protocol 
for any reason.
2. Monitoring and supervising the progress of the trial.
3. Reviewing relevant information from other sources.
4. Informing and advising the TDG on all aspects of the 
trial.
Patient and public involvement
Patients are involved in the oversight of trial progress and 
conduct via representation at periodical TDG and TSC 
meetings. Our patient representatives also provided opin-
ions on the protocol and patient- facing documentation (eg, 
Participant Information Sheet) during the set- up of the trial.
ETHICS AND DISSEMINATION
This study is being conducted in accordance with GCP, 
as defined by The International Council for Harmoni-
sation (ICH). The trial protocol has received favourable 
opinion from the South East Scotland Research Ethics 
Committee 01 (20/SS/0101; protocol number 19LJMU-
SPONSOR0094) in the UK and Clinical Research Ethics 
Board of the University of British Columbia (H20- 1936) 
in Canada. Appropriate participant information sheets 
(online supplemental file 1 (UK) and online supplemental 
file 2 (Canada)) and consent forms (online supplemental 
file 3 (UK) and online supplemental file 4 (Canada)) 
describing in detail the trial interventions, trial proce-
dures and risks were approved by the ethical committees. 
Aside from providing a participant information sheet to 
all potential participants, the investigator will explain 
the study and answer any questions posed. A contact 
point where further information about the trial may be 
obtained will be provided. After being given adequate 
time to consider the information, the participant will 
be asked to sign the informed consent document using 
the eSignature solution HELLOSIGN (UK) or REDCap 
(Canada), in line with Health Research Authority (HRA) 
advice.50 A copy of the informed consent document will 
be sent to the participants for their records, with the orig-
inal retained in the investigator site file. The participant 
may withdraw from the trial at any time by revoking their 
informed consent. The rights and welfare of the partici-
pants will be protected by emphasising to them that the 
quality of medical care will not be adversely affected if 
they decline participation.
The results will be analysed together and published 
as soon as possible. The Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals (http:// 
wwwicmje. org/) will be respected. The ISRCTN allo-
cated to this trial would be attached to any publications 
resulting from this trial.
Dissemination plan (publications, data deposition and 
curation)
It is our intention to present our research findings to all 
our research participants in a written lay summary and 
hold an open feedback session where the results will be 
presented in a lay- friendly manner. We plan to present the 
scientific findings as oral communications and abstracts 
at regional, national and international scientific meetings 
related to type 2 diabetes. We also intend to publish our 
findings in peer- reviewed journals.
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